Veerhealth Care Ltd

Key financials (Q1 FY27)

• Total revenues 25.09 crore; YoY growth 388.13%.
• EBITDA 2.07 crore; YoY growth 233.87%.
• Net profit 1.23 crore; YoY growth 412.50%.
• Net profit margin 4.90%; YoY growth 23 bps.

Outlook and guidance

• FY26-27 total income guidance: 105 crore.
• FY26-27 PAT guidance: 5-6 crore.
• FY27-28 total income guidance: 156 crore.
• FY27-28 PAT guidance: 9-10 crore.
• India-EU Trade Deal 2026 to unlock opportunities.
• Indo-Canadian JV hotel amenities supplier in advanced talks.

Key developments and operations

• USFDA clearance enables exports of OTC drugs to the USA.
• Advanced discussions with a Russian group for oral care exports.
• Production commenced at a new facility with in-house plastic molding.
• Ayuveer products onboarded on Myntra; expanding e-commerce presence.

Dematerialisation status

• Dematerialisation requests were confirmed to depositories and listed on exchanges.
• Dematerialisation certificates were mutilated and cancelled after verification, with the depository's name substituted as registered owner within timelines.

Order receipt

• Repeat order worth ₹1.11 crore from a leading nationwide pharmacy network; execution within 45 days.

FY2026-27 outlook

• Total income expected ~₹105 crore with PAT ₹5-6 crore.

FY2027-28 outlook

• Total income expected ~₹156 crore with PAT ₹9-10 crore.

Capital actions

• Preferential allotment approved for 1,00,00,000 warrants at ₹20.25 per warrant.
• Promoters subscribe 45,37,000 warrants.

Regulatory milestone

• USFDA plant clearance achieved; rare for small-cap Indian firms.

Strategic partnerships

• In advanced talks with a large Indo-Canadian hotel amenities supplier (JV).

Balance sheet impact

• FY26 BV per share ~₹11.46; warrants proceeds could raise BV substantially.

Order details

• Awarding entity not disclosed due to confidential terms.
• Nature and scope: Supply of haircare and oral care products.
• Contract value Rs 1.11 Crores (Rs 1,11,39,950).
• Awarding entity is domestic.
• Execution period: 45 days to complete.
• No promoter group interest; no related party transactions.

Warrant allotment under preferential issue

• Meeting on 2 July 2026 approved allotment of 1,00,00,000 Fully Convertible Warrants at Rs 20.25 per warrant.
• Each warrant entitles holder to subscribe to one Equity Share on conversion.
• Promoter allottees total 45,37,000 warrants.
• Non-promoter allottees total 54,63,000 warrants.
• Promoter allottee list includes six individuals.
• Non-promoter allottee list includes Akash Patel, Kusumben Shah, Ria Shah, Panna Shah.
• Total warrants issued under preferential allotment: 1,00,00,000.
• Issue price per warrant: Rs 20.25.
• The matter was considered and approved by the Preferential Issue Committee.
• Warrants are fully convertible into equity shares on exercise.